Crossmark

Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi

Crossref DOI link: https://doi.org/10.1007/s10549-025-07751-1

Published Online: 2025-06-18

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Franks, Jeffrey

Azuero, Andres

Kenzik, Kelly

Jahan, Nusrat

Fowler, Mackenzie

Griffin, Russell

Rocque, Gabrielle
License Information

Text and Data Mining valid from 2025-06-18

Version of Record valid from 2025-06-18
More Information

Article History

Received: 23 April 2025

Accepted: 25 May 2025

First Online: 18 June 2025

Declarations

:

: Dr. Rocque receives research funding from Genentech, Pfizer, Daiichi Sankyo, and Gilead Sciences. She consults with Pfizer, Gilead Sciences, and Armada/Rubicon. She is additionally employed by Atlas Oncology Partners.

: This study was approved by the University of Alabama at Birmingham Internal Review Board.

Document is current

Any future updates will be listed below